Cardiff University and Cytox to present further results on the implementation of SNPfitR analytical platform in identifying individuals for Alzheimer’s clinical trials at AD/PD conference in Lisbon

13.3.2019 06:00:00 CET | Business Wire

Del

Cytox,
a precision medicine company which today is commercializing polygenic
risk scoring (PRS) approaches for assessing genetic risk for developing
Alzheimer’s (AD) and other neurological diseases, has announced that in
collaboration with Cardiff University it will be making a poster and
short oral presentation at the multidisciplinary 14th International
Conference on Alzheimer’s and Parkinson’s Diseases and related
neurological disorders (AD/PD™
2019), March 26-31 in Lisbon, Portugal. The presentation will share
results on the high accuracy of Cytox’s pioneering SNPfitRTM,
an analytical software platform that contains multiple PRS algorithms,
in predicting clinical Alzheimer’s disease in both carriers and
non-carriers of ApoE4 risk allele, with validation and optimization in
independent, well-characterized cohorts, including the Alzheimer's
Disease Neuroimaging Initiative (ADNI). In addition, the prediction
accuracy in carriers was significantly increased compared with the
accuracy achieved using ApoE (E4/E2), age and gender.

Poster 249, ‘The Utility of Polygenic Risk Scores to Identify
Individuals for Clinical Trials in Alzheimer’s Disease’, will be
displayed all day on March 27th, as part of the ‘Imaging,
Biomarkers, Diagnostics: Other’ session in the Exhibition Hall at the
Lisbon Congress Centre and an oral presentation will be given by
Eftychia Bellou, Cardiff University, Cardiff, United Kingdom, in the
Short Oral Session 02 – Presentations of Selected Posters on March 28th,
09:15 - 11:15, Auditorium V.

Richard Pither, CEO of Cytox, commented “The importance of Cytox’s PRS
approach is gaining increasing attention for estimating individual
genetic risk profile and disease risk prediction in Alzheimer’s –
essential in the selection of individuals for clinical trials and cohort
studies. Recent results from an international collaborative study have
validated this, including how we identify Alzheimer’s disease risk in
ApoE3 homozygote individuals. The results we are presenting at AD/PD
further show that SNPfitR provides a valuable platform for determining
genetic risk in dementia in both carriers and non-carriers of ApoE4,
with the advantage of requiring only blood or saliva-extracted DNA, thus
reducing reliance on expensive PET imaging procedures.”